METTL3-Induced m6A Modification Enhances Hsa_Circ_0136959 Expression to Impair the Tumor Characteristics of Papillary Thyroid Carcinoma via Accelerating Ferroptosis
DNA and Cell Biology · 2025
DOI: 10.1089/dna.2024.0197 ↗Kurz gefasst
Fachartikel in der Zeitschrift DNA and Cell Biology, 2025. Verfasst von Lan Luo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Management (physical examination), The third People's Hospital of Hubei Province, Wuhan, China. Hauptthemen laut MEDLINE: Methyltransferases, Ferroptosis, Thyroid Cancer, Papillary, RNA, Circular. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Management (physical examination), The third People's Hospital of Hubei Province, Wuhan, China.
- Department of Endocrinology, Wuhan Third Hospital, Wuhan, China.
- Department of Endocrine, Xiangyang Hospital of Traditional Chinese Medicine (Xiangyang Institute of Traditional Chinese Medicine), Xiangyang, China.
ORCID-Profile: Zongli Cao
Zitieren
APA
Luo, L., Sun, Y., & Cao, Z. (2025). METTL3-Induced m6A Modification Enhances Hsa_Circ_0136959 Expression to Impair the Tumor Characteristics of Papillary Thyroid Carcinoma via Accelerating Ferroptosis. DNA and Cell Biology. https://doi.org/10.1089/dna.2024.0197
Vancouver
Luo L, Sun Y, Cao Z. METTL3-Induced m6A Modification Enhances Hsa_Circ_0136959 Expression to Impair the Tumor Characteristics of Papillary Thyroid Carcinoma via Accelerating Ferroptosis. DNA and Cell Biology. 2025. doi:10.1089/dna.2024.0197
BibTeX
@article{Luo2025,
author = {Luo, Lan and Sun, Yanlei and Cao, Zongli},
title = {METTL3-Induced m6A Modification Enhances Hsa_Circ_0136959 Expression to Impair the Tumor Characteristics of Papillary Thyroid Carcinoma via Accelerating Ferroptosis},
journal = {DNA and Cell Biology},
year = {2025},
doi = {10.1089/dna.2024.0197}
}
EUVIMED